Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
MAO-B Inhibitor
Methyl citrate is a potent inhibitor of Monoamine oxidase B (MAO-B), exhibiting an IC50 value of 0.23 mM. Isolated from the fruits of Opuntia ficus-indica var. saboten, this compound demonstrates significant biological activity relevant for neuropharmacological research. Methyl citrate may be utilized in studies investigating its potential effects on neurodegenerative diseases associated with dopaminergic dysfunction. -
hMAO-A Inhibitor
Obtusin is a selective and competitive inhibitor of human monoamine oxidase-A (hMAO-A) with an IC50 of 11.12 μM and a Ki of 6.15 μM. Isolated from the seeds of Cassia obtusifolia Linn, Obtusin demonstrates potential neuroprotective effects, making it relevant for research into neurodegenerative diseases, particularly those associated with anxiety and depression. Its ability to inhibit hMAO-A may contribute to the modulation of serotonin and norepinephrine levels, offering a valuable tool for elucidating mechanisms underlying mood disorders. -
MAO-A Inhibitor
MAO-A Inhibitor 1 is a selective inhibitor of monoamine oxidase A (MAO-A), exhibiting an IC50 of 100 μM. This compound is instrumental in research applications focused on neuropsychiatric disorders, where modulation of monoamine levels may offer therapeutic potential. It serves as a valuable tool in studies investigating the effects of MAO-A inhibition on neurotransmitter metabolism and related pathophysiological conditions. -
Monoamine Oxidase Inhibitor
Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A (MAO-A). This compound demonstrates significant activity in modulating neurotransmitter levels by inhibiting the oxidative deamination of monoamines, making it a valuable tool for research in neurochemistry and psychiatric disorders. Eprobemide is utilized in studies exploring depression, anxiety, and other conditions associated with monoamine imbalance. -
MAO-A/MAO-B Inhibitor
(-)-2-Phenylpropylamine is an inhibitor of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), exhibiting Ki values of 584 μM and 156 μM, respectively. This compound is utilized in research investigating neurotransmitter regulation and is of particular interest in studies related to mood disorders and neurodegenerative diseases. Its dual inhibition of MAO isoforms makes it a valuable tool for understanding the biochemical pathways involved in monoamine metabolism. -
MAO-B Inhibitor
(Rac)-Rasagiline functions as a selective inhibitor of monoamine oxidase B (MAO-B). This compound exhibits neuroprotective properties, particularly against MPTP-induced neuronal toxicity, making it a valuable tool in Parkinson's disease research. Its capacity to modulate monoaminergic systems may provide insights into therapeutic strategies for neurodegenerative disorders. -
MAO A Inhibitor
Tetrindole mesylate is a selective inhibitor of monoamine oxidase A (MAO A). It competitively inhibits rat brain mitochondrial MAO A with a Ki value of 0.4 μM, while also exhibiting weaker inhibition of MAO B with a Ki of 110 μM. This compound demonstrates antidepressant activity, making it relevant for research in psychiatric disorders and neuropharmacology. -
MAO A Inhibitor
Esuprone is a selective inhibitor of monoamine oxidase A (MAO A) with an IC50 of 7.3 nM, demonstrating significant brain penetration and oral bioavailability. This compound is valuable for neurological research, contributing to the study of mood disorders and neurodegenerative diseases by modulating neurotransmitter levels. -
MAO Inhibitor
Tetrahydroharmine is a selective monoamine oxidase (MAO) inhibitor with an IC50 value of 74 nM for MAO-A. This compound is of significant interest in the study of neurodegenerative diseases, as it may enhance monoamine neurotransmitter levels and provide neuroprotective effects. Its application in research includes exploring therapeutic strategies for conditions like depression and neurodegeneration. -
MAO-B Inhibitor
Tisolagiline monomethylsulfate is a selective, reversible inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 8 nM. It demonstrates neuroprotective effects and possesses anti-neuroinflammatory properties, making it a valuable compound for researching neurodegenerative diseases and related disorders. This reagent is suitable for studies focused on neuroprotection and inflammation modulation in various cellular and animal models. -
Monoamine Oxidase Inhibitor
Chrysophanol-1-O-β-gentiobioside is an anthraquinone glycoside that selectively inhibits the hMAO-A isozyme, exhibiting an IC50 value of 96.15 μM. This compound is primarily utilized in research focused on the modulation of monoamine oxidase activity, making it relevant for studies on neurological disorders and related pharmacological applications. Its unique structure and biological properties contribute to its potential for advancing therapeutic innovations. -
MAO-A/-B Inhibitor
MAO-IN-M30 dihydrochloride is a selective and irreversible inhibitor of monoamine oxidases A and B, with IC50 values of 37 nM and 57 nM, respectively. This compound demonstrates significant neuroprotective properties, effectively mitigating brain cell apoptosis induced by Dexamethasone. Additionally, it exhibits neurorestorative effects in models of Parkinson's disease, specifically post MPTP and lactacystin. MAO-IN-M30 dihydrochloride functions as a click chemistry reagent due to its alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) for various research applications. -
Monoamine Oxidase Inhibitor
Modaline sulfate is a potent monoamine oxidase (MAO) inhibitor that plays a significant role in the modulation of neurotransmitter levels. It has been primarily investigated for its efficacy in treating depression by preventing the breakdown of serotonin, norepinephrine, and dopamine. This compound serves as a valuable tool in research focused on mood disorders and the neurochemical pathways involved in depression. -
hMAO-B Inhibitor
Ethyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate is a selective inhibitor of human monoamine oxidase B (hMAO-B), demonstrating an IC50 of 45.52 μM. This compound is valuable in research focused on neurodegenerative diseases, as it modulates monoamine metabolism and has implications for the treatment of conditions such as Parkinson's disease. Its potent inhibition of hMAO-B makes it a useful tool for investigating the role of this enzyme in various biological processes. -
MAO-B Inhibitor
Selegiline is a potent, selective, and irreversible inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 51 nM and demonstrating 450-fold selectivity over MAO-A (IC50 = 23 μM). This compound is primarily researched for its neuroprotective effects and potential therapeutic applications in Parkinson's disease, Alzheimer's disease, and major depressive disorder. Its ability to influence dopaminergic pathways makes it a valuable reagent in studies related to neurodegeneration and mood disorders. -
MAO Inhibitor
Hydroxylamine (50% w/w in water) is a selective inhibitor of monoamine oxidase (MAO), making it valuable in research applications focused on platelet aggregation inhibition. As an important intermediate in the nitrogen cycle, it plays a role in the metabolism of aerobic ammonium-oxidizing microorganisms, including ammonium oxidizing bacteria (AOB) and complete ammonium oxidizing bacteria (comammox). Hydroxylamine also influences nitrous oxide (NO) and nitrogen gas (N2O) emissions by modulating the activity of nitrite-oxidizing bacteria (NOB). -
MAO-A Inhibitor
MAO-A Inhibitor 3 is a selective inhibitor of monoamine oxidase A (MAO-A), displaying an IC50 of greater than 100 μM. This compound is utilized in the investigation of neurological disorders, providing insights into the role of MAO-A in the metabolism of neurotransmitters and its implications in various neuropsychiatric conditions. Its application may contribute to the understanding of the biochemical pathways involved in mood regulation and depression. -
MAO-A Inhibitor
Befloxatone is a selective and reversible inhibitor of Monoamine Oxidase A (MAO-A), exhibiting an IC50 of 4 nM. By inhibiting MAO-A, Befloxatone effectively elevates the tissue levels of monoamines, including striatal dopamine and cortical norepinephrine. This compound is primarily investigated for its potential antidepressant effects, making it a valuable reagent in research related to mood disorders and neuropharmacology. -
MAO-B Inhibitor
MAO-B-IN-8 is a potent reversible inhibitor of monoamine oxidase B (MAO-B), effective in reducing the microglial production of neuroinflammatory mediators. This compound is primarily utilized in neurodegenerative disease research, making it a valuable tool for investigating therapeutic strategies aimed at modulating neuroinflammation and neuronal survival. Its ability to impact neuroinflammatory processes positions MAO-B-IN-8 as a significant reagent in the study of various neurological disorders. -
MAO-B Inhibitor
MAO-B-IN-25 is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 240 nM. It demonstrates a significantly higher selectivity for MAO-B over MAO-A, with an IC50 of 0.5 nM for the latter. This compound is valuable for research focused on neurodegenerative diseases and the modulation of monoamine neurotransmitter levels, highlighting its potential role in studying Parkinson's disease and related disorders. -
Monoamine Oxidase Inhibitor
7-Hydroxy-3,4-dihydro-2(1H)-quinolinone functions as a selective monoamine oxidase A (MAO-A) inhibitor, exhibiting an IC50 value of 183 μM. This compound primarily role in inhibiting MAO-A suggests potential applications in neuropharmacology and mood disorder research. Due to its lack of effect on MAO-B, it serves as a valuable tool in studies aimed at elucidating the distinct roles of these enzymes in monoamine metabolism. -
Monoamine Oxidase Inhibitor
Glicoricone is a phenolic compound that acts as a monoamine oxidase (MAO) inhibitor, exhibiting an IC50 of 140 μM. In addition to its primary mechanism, Glicoricone interacts with estrogen receptors (ER) and demonstrates estrogen antagonist activity. This compound is valuable for research applications focused on neurodegenerative diseases and hormonal regulation. -
Monoamine Oxidase Inhibitor
MAO-IN-1 is a selective inhibitor of monoamine oxidase B (MAO B), exhibiting an IC50 value of 20 nM. This compound plays a critical role in modulating neurochemical pathways by inhibiting the breakdown of neurotransmitters such as dopamine. Researchers can utilize MAO-IN-1 in studies related to neurodegenerative diseases, psychiatric disorders, and the exploration of metabolic processes involving monoamines. -
Ser/Thr Kinase Inhibitor
Milciclib maleate is a cyclin-dependent kinase inhibitor that primarily targets Ser/Thr kinases, disrupting cell cycle progression in melanoma. It exerts substantial antiproliferative effects by down-regulating genes such as PTTG1, thereby modulating gene expression linked to cell growth regulation. This compound enhances therapeutic sensitivity in p53-mutated melanoma cells, particularly when used in conjunction with PTTG1 silencing, making it valuable for cancer research and potential therapeutic applications. -
Ser/Thr Protease Inhibitor
IPR-803 is a potent Ser/Thr protease inhibitor that specifically targets the uPAR·uPA protein-protein interaction. By binding directly to uPAR with sub-micromolar affinity, IPR-803 effectively disrupts this critical interaction. This compound exhibits significant anti-tumor activity, making it a valuable reagent for cancer research and studies focused on protease-related pathways. -
PCSK9/HMG-CoAR Inhibitor
Dim16 is a dual inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) and HMG-CoA reductase (HMG-CoAR), demonstrating an IC50 value of 19 nM for PCSK9. It effectively inhibits the binding of PCSK9 to the LDL receptor (LDLR) with an IC50 of 0.8 nM. This compound is noted for its role in enhancing LDL uptake in HepG2 cells, making it valuable for research in cholesterol metabolism and cardiovascular diseases. -
Ser/Thr Protease Inhibitor
RWJ-58643 is a selective Ser/Thr protease inhibitor that primarily targets β-trypsin, modulating allergic inflammation pathways. This compound has demonstrated significant efficacy in reducing nasal allergy symptoms, eosinophil infiltration, and IL-5 levels at low doses, while high doses have been associated with late eosinophilia and increased IL-5 levels. RWJ-58643 functions by inhibiting the release of β-trypsin from mast cells, making it a valuable tool for research into allergic responses and related inflammatory conditions. -
MAO-B Inhibitor
Milacemide is an orally active inhibitor of monoamine oxidase B (MAO-B), classified as a glycinamide derivative. This compound demonstrates anticonvulsant effects by modulating the levels of neurotransmitters; it decreases dihydroxyphenylacetic acid and homovanilic acid while enhancing dopamine and serotonin levels in the caudate nucleus. Milacemide holds potential for research applications related to neurodegenerative disorders, particularly Alzheimer's disease. -
hMAO-B Inhibitor
hMAO-B-IN-7 is a potent inhibitor of human monoamine oxidase-B (hMAO-B) with an IC50 value of 0.79±0.05 μM. This compound effectively penetrates the blood-brain barrier, making it suitable for studies related to neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its ability to inhibit hMAO-B positions it as a valuable tool for exploring therapeutic approaches in these conditions. -
MAO-B Inhibitor
MAO-B-IN-39 is a selective monoamine oxidase B (MAO-B) inhibitor that demonstrates an IC50 of 3.61 μM. It exhibits potent induction of NRF2, contributing to its significant anti-inflammatory and neuroprotective effects in oxidative stress-related in vitro models. Additionally, MAO-B-IN-39 has shown high liver microsomal stability and favorable pharmacokinetics in murine studies, indicating its potential utility in Parkinson's disease research. -
MAO-B Inhibitor
MAO-B-IN-21 is a potent inhibitor of monoamine oxidase B (MAO-B) that also demonstrates antioxidant properties. This compound exhibits anti-amyloid-beta (Aβ) aggregation activity, metal-ion chelation, and anti-neuroinflammatory effects, specifically targeting nitric oxide and TNF-α pathways. Additionally, MAO-B-IN-21 is neuroprotective and can cross the blood-brain barrier. Its efficacy in enhancing memory and cognitive function has been established in a mouse model of Alzheimer’s disease induced by Aβ1-42. -
Monoamine Oxidase A Inhibitor
Rubrofusarin triglucoside is a glycoside compound that serves as an inhibitor of human monoamine oxidase A (hMAO-A), demonstrating an IC50 value of 85.5 μM. This compound is isolated from the seeds of Cassia obtusifolia Linn and plays a significant role in neurochemical studies related to mood regulation and depression. Its inhibition of hMAO-A makes it a valuable reagent for research into neuropharmacology and the therapeutic potential of monoamine oxidase inhibitors. -
MAO-B Inhibitor
MAO-B-IN-55 is a reversible competitive inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 2.9 nM and a remarkable 2750-fold selectivity for MAO-B over MAO-A. This compound is valuable for studying the biochemical pathways involved in Parkinson's disease, making it a significant tool for both in vitro and in vivo research applications focused on neurodegenerative disorders. -
MAO-B Inhibitor
MAO-B-IN-37 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 270 nM. This compound demonstrates favorable metabolic stability in mouse microsomes, along with strong binding affinity to human serum albumin. It is valuable for research applications focused on neurological disorders and oxidative stress, where modulation of MAO-B activity may provide therapeutic insights. -
MAO Inhibitor
SL-251131 is a reversible non-specific monoamine oxidase (MAO) inhibitor, targeting both MAO-A and MAO-B enzymes. By inhibiting these enzymes, SL-251131 temporarily increases the levels of neurotransmitters such as dopamine, making it a valuable tool for studying neurodegenerative disorders, particularly Parkinson's disease. Its application in research facilitates a deeper understanding of the biochemical pathways involved in dopaminergic signaling and related pathologies. -
MAO-B Inhibitor
Homopterocarpin is an isoflavonoid that serves as a competitive reversible inhibitor of human monoamine oxidase B (hMAO-B), with an IC50 value of 0.72 μM and a Ki of 0.21 μM. This compound demonstrates significant hepatoprotective and antioxidant properties, making it a valuable tool in studies related to liver injury and oxidative stress. Its selective inhibition of hMAO-B positions Homopterocarpin as an important reagent for exploring neurodegenerative conditions and biochemical pathways associated with cellular stress responses. -
MAO-A Inhibitor
(±)-Amiflamine serves as a potent inhibitor of monoamine oxidase-A (MAO-A), exhibiting a pIC50 value of 5.57. This compound is significant for investigating the modulation of neurotransmitter levels, making it valuable in studies related to mood disorders and neurodegenerative diseases. Its ability to inhibit MAO-A highlights its potential application in the research of therapeutic agents targeting depression and anxiety disorders. -
MAO-B Inhibitor
MAO-B-IN-13 is a potent reversible inhibitor of monoamine oxidase B (MAO-B) with an IC50 value of 10 nM, demonstrating strong blood-brain barrier penetration. This compound exhibits neuroprotective and antioxidant properties, making it a valuable tool for research focused on neurodegenerative disorders, particularly Parkinson's disease. -
MAO-A Inhibitor
Cimoxatone is a reversible and selective inhibitor of monoamine oxidase A (MAO-A), demonstrating oral bioactivity. This compound enhances the anorectic effects of serotonin, making it pertinent for studies related to appetite regulation and mood disorders. Its mechanism of action facilitates increased serotonin levels, contributing to research in neuropharmacology and potential therapeutic applications in depression and obesity. -
MAO Inhibitor
Benmoxin is a potent monoamine oxidase (MAO) inhibitor that plays a crucial role in the modulation of neurotransmitter levels. This compound is primarily utilized in depression research, offering insights into the biochemical pathways associated with mood disorders. Benmoxin serves as a valuable tool for studying the effects of MAO inhibition on neurochemical balance and potential therapeutic interventions. -
MAO-B Inhibitor
PSB-1491 is a selective and competitive inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.386 nM for human MAO-B. This compound exhibits over 25,000-fold selectivity towards MAO-B compared to MAO-A, making it a valuable tool for studying neurodegenerative diseases and exploring potential therapeutic applications in disorders such as Parkinson's disease. Its high potency and selectivity make PSB-1491 an important reagent for research focused on modulating monoamine neurotransmitter levels. -
hMAO-B Inhibitor
hMAO-B-IN-4 is a selective and reversible inhibitor of human monoamine oxidase-B (hMAO-B), demonstrating an IC50 of 0.067 µM and a Ki of 0.03 µM. It exhibits less potency against hMAO-A with an IC50 value of 33.82 µM. This compound effectively penetrates the blood-brain barrier, making it a valuable tool for research into neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. -
MAO-B Inhibitor
MAO-B-IN-33 is a potent, reversible, and selective inhibitor of monoamine oxidase-B (MAO-B) with an IC50 of 0.021 μM for MAO-B and 26.805 μM for MAO-A, highlighting its selectivity. Its distinctive action is attributed to steric hindrance caused by differences in amino acid residues between MAO-A and MAO-B. This compound effectively inhibits cerebral MAO-B activity and demonstrates the ability to mitigate MPTP-induced dopaminergic neuronal loss in murine models. MAO-B-IN-33 shows promise for applications in Parkinson's disease research. -
Monoamine Oxidase Inhibitor
(+)-Cinchonaminone acts as a monoamine oxidase inhibitor, demonstrating significant activity in the modulation of neurotransmitter levels. This compound is valuable for research applications focusing on neuropharmacology, depression, and other mood disorders, where the regulation of monoamines is critical. -
hMAO-B Inhibitor
hMAO-B-IN-2 is a potent and selective inhibitor of human monoamine oxidase B (hMAO-B), exhibiting a competitive reversible mechanism with an IC50 of 4 nM. This compound is characterized by its ability to penetrate the blood-brain barrier and demonstrates low toxicity alongside significant neuroprotective effects in SH-SY5Y neuroblastoma cells. hMAO-B-IN-2 is suitable for research applications related to Alzheimer's disease and also serves as a versatile click chemistry reagent, featuring an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. -
MAO-B Inhibitor
MAO-B-IN-16 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 1.55 µM. This compound is valuable for investigating the role of MAO-B in central nervous disorders, particularly in the context of Parkinson's disease. Its use can enhance understanding of disease mechanisms and contribute to the development of therapeutic strategies targeting MAO-B. -
MAO Inhibitor
Echitovenidine is a naturally occurring alkaloid isolated from Alstonia yunnanensis, functioning as a potent monoamine oxidase (MAO) inhibitor. This compound demonstrates significant biological activity in modulating neurotransmitter levels, making it valuable for research in neuropharmacology and the exploration of mood disorders. Echitovenidine's mechanism of action can facilitate studies aimed at understanding the role of MAO in various neurological conditions. -
MAO-B Inhibitor
1-Methyl-2-undecyl-4(1H)-quinolone is a selective and irreversible inhibitor of type B monoamine oxidase (MAO-B). It exhibits potent inhibition with IC50 and Ki values of 15.3 μM and 9.91 μM, respectively, without affecting type A monoamine oxidase (MAO-A) activity. This quinolone alkaloid, derived from the fresh leaves and fruits of Evodia rutaecarpa, is valuable in research focused on neurological disorders and the modulation of neurotransmitter levels. -
MAO A/B Inhibitor
MAO-IN-3 is a reversible and competitive inhibitor of monoamine oxidase A and B, exhibiting Ki values of 0.6 μM and 0.2 μM, respectively. This compound demonstrates significant anti-proliferative effects on LN-229 glioblastoma cells, with an IC50 of 0.8 μM. MAO-IN-3 is suitable for research applications focused on cancer biology and therapeutic development targeting monoamine oxidase pathways. -
MAO-B Inhibitor
MAO-B-IN-14 is a selective monoamine oxidase-B (MAO-B) inhibitor, exhibiting an IC50 of 0.95 μM and a Ki of 0.55 μM against human MAO-B. This compound demonstrates significant potential for research applications focused on neurodegenerative disorders, particularly those involving dopaminergic pathways. Its inhibitory properties make it a valuable tool for studies exploring the role of MAO-B in neurological conditions and therapeutic interventions targeting this enzyme.
